Dr Rahul Naren Desai, MD | |
8950 Sw Nimbus Ave, 150, Beaverton, OR 97008-7478 | |
(503) 535-8302 | |
(503) 416-8732 |
Full Name | Dr Rahul Naren Desai |
---|---|
Gender | Male |
Speciality | Diagnostic Radiology |
Experience | 22 Years |
Location | 8950 Sw Nimbus Ave, Beaverton, Oregon |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1275551061 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2085R0202X | Radiology - Diagnostic Radiology | 35.083561 (Ohio) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Restore Interventional Spineand Sports Medicine Llc | 0244472181 | 3 |
News Archive
Today, Highmark Inc. closed its merger with Blue Cross of Northeastern Pennsylvania (BCNEPA) after securing approval from the Pennsylvania Insurance Department. The merged company will operate as Highmark Blue Cross Blue Shield and continue to provide health insurance coverage and administrative services to nearly 550,000 individuals in the 13 counties of northeastern Pennsylvania.
The National Cancer Institute today announced that a team co-led by Fred Hutchinson Cancer Research Center and The Broad Institute in Cambridge, Mass., has been selected to participate in a National Cancer Institute-funded research consortium dedicated to understanding the molecular basis of cancer.
A review of measures taken to address a 2004 outbreak of the highly infectious Norwalk virus at The Johns Hopkins Hospital has provided the first solid documentation of expenses and efforts in the United States to stop the infection from spreading among patients, staff and visitors.
Arena Pharmaceuticals, Inc. reported that positive data from a clinical trial evaluating the abuse potential of lorcaserin were presented in a poster session at the 48th Annual Meeting of the American College of Neuropsychopharmacology. Data from the trial demonstrate that the risk for abuse associated with lorcaserin is very low.
Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the United States.
› Verified 1 days ago
Entity Name | Epic Imaging Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1700983319 PECOS PAC ID: 6608766423 Enrollment ID: O20040317000014 |
News Archive
Today, Highmark Inc. closed its merger with Blue Cross of Northeastern Pennsylvania (BCNEPA) after securing approval from the Pennsylvania Insurance Department. The merged company will operate as Highmark Blue Cross Blue Shield and continue to provide health insurance coverage and administrative services to nearly 550,000 individuals in the 13 counties of northeastern Pennsylvania.
The National Cancer Institute today announced that a team co-led by Fred Hutchinson Cancer Research Center and The Broad Institute in Cambridge, Mass., has been selected to participate in a National Cancer Institute-funded research consortium dedicated to understanding the molecular basis of cancer.
A review of measures taken to address a 2004 outbreak of the highly infectious Norwalk virus at The Johns Hopkins Hospital has provided the first solid documentation of expenses and efforts in the United States to stop the infection from spreading among patients, staff and visitors.
Arena Pharmaceuticals, Inc. reported that positive data from a clinical trial evaluating the abuse potential of lorcaserin were presented in a poster session at the 48th Annual Meeting of the American College of Neuropsychopharmacology. Data from the trial demonstrate that the risk for abuse associated with lorcaserin is very low.
Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the United States.
› Verified 1 days ago
Entity Name | Restore Interventional Spine& Sports Medicine Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1801139019 PECOS PAC ID: 0244472181 Enrollment ID: O20130806000571 |
News Archive
Today, Highmark Inc. closed its merger with Blue Cross of Northeastern Pennsylvania (BCNEPA) after securing approval from the Pennsylvania Insurance Department. The merged company will operate as Highmark Blue Cross Blue Shield and continue to provide health insurance coverage and administrative services to nearly 550,000 individuals in the 13 counties of northeastern Pennsylvania.
The National Cancer Institute today announced that a team co-led by Fred Hutchinson Cancer Research Center and The Broad Institute in Cambridge, Mass., has been selected to participate in a National Cancer Institute-funded research consortium dedicated to understanding the molecular basis of cancer.
A review of measures taken to address a 2004 outbreak of the highly infectious Norwalk virus at The Johns Hopkins Hospital has provided the first solid documentation of expenses and efforts in the United States to stop the infection from spreading among patients, staff and visitors.
Arena Pharmaceuticals, Inc. reported that positive data from a clinical trial evaluating the abuse potential of lorcaserin were presented in a poster session at the 48th Annual Meeting of the American College of Neuropsychopharmacology. Data from the trial demonstrate that the risk for abuse associated with lorcaserin is very low.
Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the United States.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Rahul Naren Desai, MD 8950 Sw Nimbus Ave, 150, Beaverton, OR 97008-7478 Ph: (503) 535-8302 | Dr Rahul Naren Desai, MD 8950 Sw Nimbus Ave, 150, Beaverton, OR 97008-7478 Ph: (503) 535-8302 |
News Archive
Today, Highmark Inc. closed its merger with Blue Cross of Northeastern Pennsylvania (BCNEPA) after securing approval from the Pennsylvania Insurance Department. The merged company will operate as Highmark Blue Cross Blue Shield and continue to provide health insurance coverage and administrative services to nearly 550,000 individuals in the 13 counties of northeastern Pennsylvania.
The National Cancer Institute today announced that a team co-led by Fred Hutchinson Cancer Research Center and The Broad Institute in Cambridge, Mass., has been selected to participate in a National Cancer Institute-funded research consortium dedicated to understanding the molecular basis of cancer.
A review of measures taken to address a 2004 outbreak of the highly infectious Norwalk virus at The Johns Hopkins Hospital has provided the first solid documentation of expenses and efforts in the United States to stop the infection from spreading among patients, staff and visitors.
Arena Pharmaceuticals, Inc. reported that positive data from a clinical trial evaluating the abuse potential of lorcaserin were presented in a poster session at the 48th Annual Meeting of the American College of Neuropsychopharmacology. Data from the trial demonstrate that the risk for abuse associated with lorcaserin is very low.
Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the United States.
› Verified 1 days ago
Gilbert Willard Eklund, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 1500 Nw Bethany Blvd, 100, Beaverton, OR 97006 Phone: 503-619-1100 Fax: 503-619-1101 | |
Jane E Bedell, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 1500 Nw Bethany Blvd, Ste 100, Beaverton, OR 97006 Phone: 503-619-1100 Fax: 503-619-1101 | |
Paul Anthony Meunier, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 1500 Nw Bethany Blvd, Ste 100, Beaverton, OR 97006 Phone: 503-619-1100 Fax: 503-619-1101 | |
Dr. Kellie Schenk, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 8950 Sw Nimbus Ave, Beaverton, OR 97008 Phone: 503-253-1105 | |
Jay A Bocchi, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 8950 Sw Nimbus Avenue, Beaverton, OR 97008 Phone: 503-643-7226 Fax: 503-626-5239 |